Nordea Investment Management Ab Uni Qure N.V. Transaction History

Nordea Investment Management Ab

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	BUY	$6.71 - $11.83 $3,012 - $5,311	449 Added 0.15%	297,267 $1.99 Million
Q2 2023 Jul 07, 2023	BUY	$11.12 - $22.2 $158,237 - $315,906	14,230 Added 5.04%	296,818 $3.4 Million
Q1 2023 Apr 19, 2023	SELL	$18.7 - $23.07 $38,447 - $47,431	-2,056 Reduced 0.72%	282,588 $5.69 Million
Q4 2022 Feb 08, 2023	BUY	$18.12 - $27.32 $126,405 - $190,584	6,976 Added 2.51%	284,644 $6.45 Million
Q3 2022 Oct 19, 2022	SELL	$16.98 - $25.54 $14,568 - $21,913	-858 Reduced 0.31%	277,668 $5.17 Million
Q2 2022 Aug 09, 2022	BUY	$13.15 - $20.45 $28,285 - $43,987	2,151 Added 0.78%	278,526 $5.05 Million
Q1 2022 Apr 11, 2022	BUY	$14.54 - $21.5 $52,256 - $77,271	3,594 Added 1.32%	276,375 $5.06 Million
Q4 2021 Jan 20, 2022	SELL	$20.24 - $36.01 $83,996 - $149,441	-4,150 Reduced 1.5%	272,781 $5.86 Million
Q3 2021 Nov 01, 2021	SELL	$26.01 - $38.22 $7.2 Million - $10.6 Million	-276,931 Reduced 50.0%	276,931 $8.91 Million
Q3 2021 Nov 01, 2021	BUY	$26.01 - $38.22 $8.54 Million - $12.6 Million	328,395 Added 145.65%	553,862 $17.7 Million
Q2 2021 Jul 16, 2021	BUY	$29.97 - $37.17 $6.76 Million - $8.38 Million	225,467 New	225,467 $6.94 Million

155

40.8M

925K

617K

Ticker QURE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,729,100
Market Cap $740M
Description
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...

Get notified when there are updates to the investment portfolio of Nordea Investment Management Ab, based on Form 13F filings with the SEC.

Stay updated on Nordea Investment Management Ab with notifications on news.